Glybera Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
XENE | D | Xenon Pharmaceuticals Inc. | 0.10 | |
QURE | F | uniQure N.V. | -0.64 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
IBRN | D | iShares Neuroscience and Healthcare ETF | 4.02 | |
PBE | D | PowerShares Dynamic Biotech & Genome | 2.42 | |
SBIO | D | ALPS Medical Breakthroughs ETF | 2.05 | |
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 1.27 | |
MMSC | B | First Trust Multi-Manager Small | 0.84 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Apr 16 | XENE | Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting |
- Glybera
Alipogene tiparvovec (marketed under the trade name Glybera) is a gene therapy treatment designed to reverse lipoprotein lipase deficiency (LPLD), a rare inherited disorder which can cause severe pancreatitis. In July 2012, the European Medicines Agency recommended it for approval (the first recommendation for a gene therapy treatment in either Europe or the United States), and the recommendation was endorsed by the European Commission in November 2012.The drug is administered via a series of injections into the leg muscles—as many as 60, all in one session. It is a one-time treatment intended to last at least ten years.
Glybera gained infamy as the "million-dollar drug," causing its manufacturer, uniQure, to remove the drug after two years on the European market. As of 2018, only 31 people worldwide have ever been administered Glybera, and uniQure has no plans to sell the drug in the US or Canada.
Popular Now
Recent Comments
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
- TraderMike on Market Recap for Friday, March 8, 2024
- Don_Marat on Market Recap for Friday, March 8, 2024
From the Blog
Featured Articles